Hostname: page-component-54dcc4c588-nx7b4 Total loading time: 0 Render date: 2025-10-09T11:23:44.687Z Has data issue: false hasContentIssue false

GR.6 Deep brain stimulation of the nucleus accumbens for severe self-injurious behaviour in children: a phase I pilot trial

Published online by Cambridge University Press:  10 July 2025

K Mithani
Affiliation:
(Toronto)*
C Gorodetsky
Affiliation:
(Toronto)
S Breitbart
Affiliation:
(Toronto)
H Yan
Affiliation:
(Toronto)
K Zhang
Affiliation:
(Toronto)
FV Gouveia
Affiliation:
(Toronto)
N Warsi
Affiliation:
(Toronto)
H Suresh
Affiliation:
(Toronto)
SM Wong
Affiliation:
(Toronto)
J Huber
Affiliation:
(Toronto)
EN Kerr
Affiliation:
(Toronto)
AV Kulkarni
Affiliation:
(Toronto)
MJ Taylor
Affiliation:
(Toronto)
L Hagopian
Affiliation:
(Baltimore)
A Fasano
Affiliation:
(Toronto)
GM Ibrahim
Affiliation:
(Toronto)
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Self-injurious behaviours (SIB) are repetitive, non-accidental movements that result in physical damage inflicted upon oneself, without suicidal intent. SIB are prevalent among children with autism spectrum disorder and can lead to permanent disability or death. Neuromodulation at a locus of neural circuitry implicated in SIB, the nucleus accumbens (NAc), may directly influence these behaviours. Methods: We completed a phase I, open-label clinical trial of deep brain stimulation (DBS) of the NAc in children with severe, treatment-refractory SIB (ClinicalTrials.gov NCT03982888). Participants were monitored for 12 months following NAc-DBS to assess the primary outcomes of safety and feasibility. Secondary outcomes included serial assessments of SIB, ambulatory actigraphy, and changes in brain glucose metabolism induced by DBS. Results: Six children underwent NAc-DBS without any serious adverse events. NAc-DBS resulted in significant reductions in SIB and SIB-associated behaviours across multiple standardized scales, concurrent with clinically meaningful improvements in quality-of-life. Ambulatory actigraphy showed reductions in high-amplitude limb movements and positron emission tomography revealed treatment-induced reductions in metabolic activity within the thalamus, striatum, and temporoinsular cortex. Conclusions: This first-in-children phase 1 clinical trial demonstrates the safety and feasibility of NAc-DBS in children with severe, refractory SIB at high risk of physical injury and death and supports further investigations.

Information

Type
Abstracts
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation